136 related articles for article (PubMed ID: 33370688)
1. Development and validation of a UPLC-MS/MS method for quantification of C-005, a novel third-generation EGFR TKI, and its major metabolite in plasma: Application to its first-in-patient study.
Wang Z; Ye W; Qin Y; You H; Zhang S; Fan F; Wang Y; Zheng L
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122475. PubMed ID: 33370688
[TBL] [Abstract][Full Text] [Related]
2. Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic study.
Cui X; Wang S; Gao H; Li B; Shi Y; Guo H; Song T; Zheng X
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122488. PubMed ID: 33360679
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of dacomitinib and its major metabolite, O-desmethyl dacomitinib in human plasma by LC-MS/MS and its application to clinical testing in patients with non-small cell lung cancer.
Feng X; Ding Y; Zhang P; Fu Q; Zhang L; Zheng H
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122940. PubMed ID: 34564058
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats.
Ezzeldin E; Iqbal M; Al-Salahi R; El-Nahhas T
J Pharm Biomed Anal; 2019 Mar; 166():244-251. PubMed ID: 30665192
[TBL] [Abstract][Full Text] [Related]
7. Development of an LC-MS/MS method for quantifying two main metabolites of abivertinib in human plasma.
Zheng X; Wang W; Zhang Y; Ma Y; Zhao H; Gao H; Hu P; Jiang J
Biomed Chromatogr; 2020 Feb; 34(2):e4704. PubMed ID: 31629371
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma.
Zheng X; Wang W; Zhang Y; Ma Y; Zhao H; Hu P; Jiang J
Biomed Chromatogr; 2018 Dec; 32(12):e4365. PubMed ID: 30119142
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous quantification of vortioxetine, fluoxetine and their metabolites in rat plasma by UPLC-MS/MS.
Wang Q; Chen Z; Chen D; Luo S; Xie L
Biomed Chromatogr; 2020 Dec; 34(12):e4960. PubMed ID: 32729624
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS/MS method and its application to human microsomal metabolic stability study.
Ezzeldin E; Iqbal M; Herqash RN; ElNahhas T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1136():121851. PubMed ID: 31812004
[TBL] [Abstract][Full Text] [Related]
11. Development of an UPLC-MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients.
Wang W; Zheng X; Wang H; Wang L; Jiang J; Hu P
J Pharm Biomed Anal; 2017 May; 139():205-214. PubMed ID: 28285073
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients.
Cui X; Zheng X; Jiang J; Tan F; Ding L; Hu P
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Nov; 1068-1069():33-40. PubMed ID: 29028616
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
[TBL] [Abstract][Full Text] [Related]
14. An UPLC-MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients.
Cui C; Hu P; Jiang J; Kong F; Luo H; Zhao Q
J Pharm Biomed Anal; 2018 May; 153():1-8. PubMed ID: 29455091
[TBL] [Abstract][Full Text] [Related]
15. Determination of tyrosine kinase inhibitor afatinib in rat plasma using LC-MS/MS and its application to in vivo pharmacokinetic studies of afatinib liposomes.
Lu X; Liu S; Yang X; Han M; Sun K
J Pharm Biomed Anal; 2019 Feb; 164():181-186. PubMed ID: 30390560
[TBL] [Abstract][Full Text] [Related]
16. A rapid UHPLC-MS/MS method for the quantification of ARQ531 in rat plasma: Validation and its application to a pharmacokinetic study.
Liu J; Ji M; Li Z; Xu X; Li L; Li H; Tian Y; Su X
Biomed Chromatogr; 2020 Nov; 34(11):e4937. PubMed ID: 32614971
[TBL] [Abstract][Full Text] [Related]
17. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
[TBL] [Abstract][Full Text] [Related]
18. Determination of BPI15086 and its metabolite in human plasma by ultra-high performance liquid chromatography-MS/MS and its application to a pharmacokinetic study.
Wang S; Zheng X; Zhang Y; Hu P; Ding L; Mao L; Jiang J
Bioanalysis; 2019 Apr; 11(8):773-784. PubMed ID: 30994009
[No Abstract] [Full Text] [Related]
19. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.
Gurav SD; Gilibili RR; Jeniffer S; Giri S; Srinivas NR; Mullangi R
Biomed Chromatogr; 2011 Jul; 25(7):794-800. PubMed ID: 20872957
[TBL] [Abstract][Full Text] [Related]
20. UPLC-MS/MS determination of thiamphenicol in human plasma and its application to a pharmacokinetic study.
Wang Z; Yang H; Sun W; Huang CK; Cui X; Qiu XJ; Lian QQ; Wang ZS
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 967():235-9. PubMed ID: 25129408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
